Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women
Phase of Trial: Phase I
Latest Information Update: 28 May 2016
At a glance
- Drugs BAY 1128688 (Primary)
- Indications Endometriosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 18 May 2016 Status changed from active, no longer recruiting to completed.
- 31 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 04 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.